Tandospiaine antidepressive therapy

• US 5,330,762 A
• Filed: 01/27/1993
• Issued: 07/19/1994
• Est. Priority Date: 02/27/1992
• Status: Expired due to Term

• Current Assignee: Encinal Pharmaceutical Investments, LLC
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Ayer, Atul D., Ridzon, Dana
• Primary Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US08/010,086
• Time in Patent Office: 538 Days
• Field of Search: 424/473, 424/472, 424/480, 424/482
• US Class Current: 424/473
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine

Abstract

A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient.

Claims

1. An osmotic dosage form for administering tandospirone to a patient in need of tandospirone therapy, wherein the dosage form comprises:

(a) a wall comprising a member selected from the group consisting of cellulose acetate, cellulose diacetate, and cellulose triacetate, which wall forms;

(b) an internal compartment;

(c) at least one exit passageway in the wall that connects the exterior of the dosage form with the compartment;

(d) a push composition in the compartment comprising a composition that, in the presence of fluid that enters the compartment, increases in dimensions and thereby occupies space in the compartment; and

wherein the osmotic dosage form is characterized by;

(e) a tandospirone composition comprising 1 mg to 750 mg of tandospirone and a polyethylene oxide polymer comprising a 190,000 to 210,000 molecular weight pressed into a layer that provides a dispensable tandospirone composition for administering, when the dosage form is in operation, to the patient in need of tandospirone therapy at a controlled rate over a period up to thirty hours.

2. The osmotic dosage form for administering tandospirone to the patient according to claim 1, wherein the tandospirone composition comprises polyvinyl pyrrolidone.

3. The osmotic dosage form for administering tandospirone to the patient according to claim 1, wherein the tandospirone composition comprises butylated hydroxytoleune.

4. The osmotic dosage form for administering tandospirone to the patient according to claim 1, wherein the tandospirone composition comprises a lubricant.

5. The osmatic dosage form for administering tandospirone to the patient according to claim 1, wherein the polyethylene oxide comprises a 200,000 molecular weight.

6. The osmotic dosage form for administering tandospirone to the patient according to claim 1, wherein tandospirone is present as a therapeutically acceptable salt.